Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors

This study will enroll patients initiating Bruton Tyrosine Kinase (BTK) inhibitors without history of documented arrhythmia while on therapy using the Medtronic LINQ-2 insertable cardiac monitor (ILR). The incidence of new onset atrial fibrillation (AF) and other arrhythmia will be determined. Actions taken in response to device detected arrhythmia will be recorded.

Inclusion Criteria:>18yoWilling to sign and date consent form,Willing to be remotely monitoredInitiating BTK inhibitor for approved condition (i.e. CLL, Waldenstrom's, etc)Willing to have Medtronic cardiac monitor inserted to allow at minimum 24 hours continuous monitoring prior to initiating BTK inhibitorExclusion Criteria:Documented AF/VA in past 12 monthsCerebral Vascular Accident (CVA) or Transient Ischemic Attack (TIA) in past yearHas current implanted pulse generator, defibrillator, pacemaker, or resynchronization deviceheart surgery within past 90 daysMyocardial Infarction within past 90 daysPatient is taking an anti-arrhythmic or anticoagulanthas concomitant condition that precludes safe participation in study (substance abuse, etc)Enrollment in separate study that could confound results of this study